Overview

Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
An open-label randomized Phase II study in order to explore two different sequential anthracycline-based neoadjuvant treatment regimens in female patients with primary, operable breast cancer (T2-T4/N0-2/M0).
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cyclophosphamide
Docetaxel
Doxorubicin
Liposomal doxorubicin
Pemetrexed